WO2002028853A1 - Compose de benzylamine, son procede de production et produit intermediaire correspondant - Google Patents

Compose de benzylamine, son procede de production et produit intermediaire correspondant Download PDF

Info

Publication number
WO2002028853A1
WO2002028853A1 PCT/JP2001/008616 JP0108616W WO0228853A1 WO 2002028853 A1 WO2002028853 A1 WO 2002028853A1 JP 0108616 W JP0108616 W JP 0108616W WO 0228853 A1 WO0228853 A1 WO 0228853A1
Authority
WO
WIPO (PCT)
Prior art keywords
producing
benzylamine compound
same
halogeno
intermediate therefor
Prior art date
Application number
PCT/JP2001/008616
Other languages
English (en)
Japanese (ja)
Inventor
Masami Takahashi
Masakatsu Sugahara
Hiroshi Mizuuchi
Akira Saito
Taketoshi Ishii
Original Assignee
Tanabe Seiyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co., Ltd. filed Critical Tanabe Seiyaku Co., Ltd.
Priority to AU2001292320A priority Critical patent/AU2001292320A1/en
Publication of WO2002028853A1 publication Critical patent/WO2002028853A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

L'invention concerne un composé de benzylamine (ou un sel de celui-ci acceptable sur le plan pharmaceutique) représenté par la formule générale (I), dans laquelle R1 représente un groupe hétérocyclique aromatique condensé qui comporte entre un et quatre hétéroatomes sélectionnés parmi des atomes d'azote, d'oxygène et de soufre, et qui est éventuellement substitué par halogéno, oxo, nitro, cyano, alkyle inférieur, halogénoalkyle inférieur, alcoxy inférieur, pyridyle, etc.; R2 et R3 représentant chacun hydrogène, halogéno, alkyle inférieur, halogénoalkyle inférieur, ou alcoxy inférieur.
PCT/JP2001/008616 2000-10-02 2001-10-01 Compose de benzylamine, son procede de production et produit intermediaire correspondant WO2002028853A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001292320A AU2001292320A1 (en) 2000-10-02 2001-10-01 Benzylamine compound, process for producing the same, and intermediate therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000301563 2000-10-02
JP2000-301563 2000-10-02

Publications (1)

Publication Number Publication Date
WO2002028853A1 true WO2002028853A1 (fr) 2002-04-11

Family

ID=18783085

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/008616 WO2002028853A1 (fr) 2000-10-02 2001-10-01 Compose de benzylamine, son procede de production et produit intermediaire correspondant

Country Status (2)

Country Link
AU (1) AU2001292320A1 (fr)
WO (1) WO2002028853A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030695A1 (fr) * 2002-10-04 2004-04-15 The University Of Reading Traitement de maladies vasculaires
WO2005016862A1 (fr) * 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Derive d'acide arylalcanoique substitue et son utilisation
WO2005034869A3 (fr) * 2003-10-08 2005-07-07 Irm Llc Composes et compositions convenant comme inhibiteurs de proteine-kinases
WO2008090117A1 (fr) 2007-01-24 2008-07-31 Glaxo Group Limited Nouvelles compositions pharmaceutiques
US7645764B2 (en) 2006-11-09 2010-01-12 Roche Palo Alto Llc Kinase inhibitors and methods for using the same
US7678792B2 (en) 2006-10-20 2010-03-16 Irm Llc Compositions and methods for modulating c-kit and PDGFR receptors
US8158828B2 (en) 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
JP2012533541A (ja) * 2009-07-15 2012-12-27 インテリカイン， エルエルシー 特定の化学物質、組成物および方法
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
AU2011265521B2 (en) * 2005-07-15 2013-10-31 Merck Serono Sa JNK inhibitors for the treatment of endometreosis
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9527847B2 (en) 2012-06-25 2016-12-27 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9822131B2 (en) 2008-01-04 2017-11-21 Intellikine Llc Certain chemical entities, compositions and methods
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009844A1 (fr) * 1990-01-04 1991-07-11 Pfizer Inc. Antagonistes de la substance p
WO1992017449A1 (fr) * 1991-03-26 1992-10-15 Pfizer Inc. Preparation stereoselective de piperidines substituees
WO1994004496A1 (fr) * 1992-08-19 1994-03-03 Pfizer Inc. Benzylamino azote substitue renfermant des heterocycles non aromatiques
WO1994013663A1 (fr) * 1992-12-10 1994-06-23 Pfizer Inc. Heterocycles non aromatiques substitues par aminomethylene et leur utilisation comme antagonistes de substance p
WO1995008549A1 (fr) * 1993-09-22 1995-03-30 Glaxo Group Limited Derives de la 3-(5-tetrazolyl-benzyl)amino-piperidine et antagonistes de tachykinines
WO1997001554A1 (fr) * 1995-06-28 1997-01-16 Merck Sharp & Dohme Limited Derives de piperidine et de morpholine, et leur utilisation comme agents therapeutiques
WO1997021702A1 (fr) * 1995-12-11 1997-06-19 Merck Sharp & Dohme Limited 3-benzylamino-pyrrolidines et piperidines utilisees comme antagonistes des recepteurs des tachykinines

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009844A1 (fr) * 1990-01-04 1991-07-11 Pfizer Inc. Antagonistes de la substance p
WO1992017449A1 (fr) * 1991-03-26 1992-10-15 Pfizer Inc. Preparation stereoselective de piperidines substituees
WO1994004496A1 (fr) * 1992-08-19 1994-03-03 Pfizer Inc. Benzylamino azote substitue renfermant des heterocycles non aromatiques
WO1994013663A1 (fr) * 1992-12-10 1994-06-23 Pfizer Inc. Heterocycles non aromatiques substitues par aminomethylene et leur utilisation comme antagonistes de substance p
WO1995008549A1 (fr) * 1993-09-22 1995-03-30 Glaxo Group Limited Derives de la 3-(5-tetrazolyl-benzyl)amino-piperidine et antagonistes de tachykinines
WO1997001554A1 (fr) * 1995-06-28 1997-01-16 Merck Sharp & Dohme Limited Derives de piperidine et de morpholine, et leur utilisation comme agents therapeutiques
WO1997021702A1 (fr) * 1995-12-11 1997-06-19 Merck Sharp & Dohme Limited 3-benzylamino-pyrrolidines et piperidines utilisees comme antagonistes des recepteurs des tachykinines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARBONNELLE A.C. ET AL., TETRAHEDRON LETT., vol. 39, no. 25, 1998, pages 4467 - 4470, XP002912910 *
CHEMICAL ABSTRACTS, vol. 51, Columbus, Ohio, US; abstract no. 8081F-8082C, XP002906375 *
SCI. PROC. ROY. DUBLIN SOC., vol. 27, 1956, pages 111 - 117 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030695A1 (fr) * 2002-10-04 2004-04-15 The University Of Reading Traitement de maladies vasculaires
US7470807B2 (en) 2003-08-14 2008-12-30 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivatives and use thereof
JP2007528362A (ja) * 2003-08-14 2007-10-11 旭化成ファーマ株式会社 置換アリールアルカン酸誘導体及びその用途
WO2005016862A1 (fr) * 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Derive d'acide arylalcanoique substitue et son utilisation
US7449582B2 (en) 2003-10-08 2008-11-11 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2007508310A (ja) * 2003-10-08 2007-04-05 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
WO2005034869A3 (fr) * 2003-10-08 2005-07-07 Irm Llc Composes et compositions convenant comme inhibiteurs de proteine-kinases
AU2004279427B2 (en) * 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
JP4758349B2 (ja) * 2003-10-08 2011-08-24 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
AU2011265521B2 (en) * 2005-07-15 2013-10-31 Merck Serono Sa JNK inhibitors for the treatment of endometreosis
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US8158828B2 (en) 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US9051267B2 (en) 2005-11-28 2015-06-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US7678792B2 (en) 2006-10-20 2010-03-16 Irm Llc Compositions and methods for modulating c-kit and PDGFR receptors
US8106068B2 (en) 2006-10-20 2012-01-31 Irm Llc Compositions and methods for modulating c-kit and PDGFR receptors
US7645764B2 (en) 2006-11-09 2010-01-12 Roche Palo Alto Llc Kinase inhibitors and methods for using the same
WO2008090117A1 (fr) 2007-01-24 2008-07-31 Glaxo Group Limited Nouvelles compositions pharmaceutiques
US9655892B2 (en) 2008-01-04 2017-05-23 Intellikine Llc Certain chemical entities, compositions and methods
US11433065B2 (en) 2008-01-04 2022-09-06 Intellikine Llc Certain chemical entities, compositions and methods
US9216982B2 (en) 2008-01-04 2015-12-22 Intellikine Llc Certain chemical entities, compositions and methods
US9822131B2 (en) 2008-01-04 2017-11-21 Intellikine Llc Certain chemical entities, compositions and methods
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9522146B2 (en) 2009-07-15 2016-12-20 Intellikine Llc Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9206182B2 (en) 2009-07-15 2015-12-08 Intellikine Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
JP2012533541A (ja) * 2009-07-15 2012-12-27 インテリカイン， エルエルシー 特定の化学物質、組成物および方法
US9840505B2 (en) 2011-01-10 2017-12-12 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
USRE46621E1 (en) 2011-01-10 2017-12-05 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US10550122B2 (en) 2011-01-10 2020-02-04 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof
US11312718B2 (en) 2011-01-10 2022-04-26 Infinity Pharmaceuticals, Inc. Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
US9527847B2 (en) 2012-06-25 2016-12-27 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US11944631B2 (en) 2014-04-16 2024-04-02 Infinity Pharmaceuticals, Inc. Combination therapies
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies

Also Published As

Publication number Publication date
AU2001292320A1 (en) 2002-04-15

Similar Documents

Publication Publication Date Title
WO2002028853A1 (fr) Compose de benzylamine, son procede de production et produit intermediaire correspondant
WO2002024650A3 (fr) Derives de pyridinone et de pyridinethione presentant des proprietes inhibitrices du vih
AU3053999A (en) Nitrogenous heterocyclic compounds
WO2005105096A3 (fr) Composes heterocycliques fusionnes
WO2002044153A8 (fr) Derives de 4-aryle pyridine
AP2001002205A0 (en) Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase.
WO2003064429A1 (fr) Thienopyrimidines, procedes de fabrication et d'utilisation correspondants
EP1640366A4 (fr) Derive de methyle sulfone heterocyclique
EP1043312A4 (fr) Composes heterocycliques a activites inhibant nos
CA2273303A1 (fr) Composes thienylsulfonylamino(thio)carbonyles
AU9025601A (en) Cephem compounds and esbl-detecting reagents containing the same
HUT75649A (en) Optically active imidazolidinone derivative and pharmaceutical compositions containing them
EP1043311A4 (fr) Derives de biphenylamidine
DK1338596T3 (da) Fremgangsmåde til fremstilling af antibakterielt middel af carbapenemtypen
TW200740757A (en) Carboxamide compound and use of the same
YU64699A (sh) Kvaternarna jedinjenja amonijuma kao tahikininski antagonisti
WO2001010861A3 (fr) Heterocyclyl-2h-chromenes substitues
EP1211253A4 (fr) Derives dihydrobenzofuran tricycliques, leur procede de preparation et agents
WO2007007903A3 (fr) Compose de carboxamide et utilisation
DE60130916D1 (de) Neue beta-lactamverbindungen und verfahren zu deren herstellung
AU3648093A (en) Pyrrolidine derivatives useful as 5-HT3-antagonists
WO2003004464A8 (fr) Derives d'amide heterocycliques
WO2000043375A3 (fr) Composes heterocycliques d'aryle substitues
DK0661273T3 (da) Indanderivater og fremgangsmåder til fremstilling af samme
WO2002051822A3 (fr) Isothiazolecarboxamides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS KR LC LK LR LT LV MA MG MK MN MX NO NZ PH PL RO SG SI SK TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase